NewAmsterdam Pharma (NAMS) EBIT (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted EBIT of -$58.4 million for Q1 2026, up 11.46% sequentially from -$66.0 million in Q4 2025, and up 15.24% YoY from -$50.7 million in Q1 2025.
NewAmsterdam Pharma (NAMS) EBIT (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported EBIT for 4 years, with the latest figure at -$58.4 million in Q1 2026.
- Quarterly EBIT rose 15.24% year-over-year to -$58.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.2 million (down 13.41% YoY) and the FY2025 annual result came in at -$225.7 million, down 28.02% from the prior year.
- EBIT advanced to -$58.4 million in Q1 2026 per NAMS's latest filing, from -$66.0 million in the prior quarter.
- Over five years, EBIT peaked at -$25.0 million in Q3 2024 and troughed at -$68.9 million in Q1 2025.
- A 4-year average of -$49.5 million and a median of -$51.1 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT soared 49.55% in 2024, then sank 120.55% in 2025.
- Over 4 years, EBIT stood at -$51.1 million in 2023, then advanced by 15.36% to -$43.2 million in 2024, then sank by 52.63% to -$66.0 million in 2025, then climbed by 11.46% to -$58.4 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$58.4 million, -$66.0 million, and -$55.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | -64.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -64.86 Mn |
| Mar 31, 2026 | -58.42 Mn |
| Dec 31, 2025 | -65.98 Mn |
| Sep 30, 2025 | -55.14 Mn |
| Jun 30, 2025 | -35.64 Mn |
| Mar 31, 2025 | -68.93 Mn |
| Dec 31, 2024 | -43.23 Mn |
| Sep 30, 2024 | -25.00 Mn |
| Jun 30, 2024 | -52.58 Mn |
| Mar 31, 2024 | -55.48 Mn |
| Dec 31, 2023 | -51.07 Mn |
| Sep 30, 2023 | -49.56 Mn |
| Jun 30, 2023 | -42.48 Mn |
| Mar 31, 2023 | -39.85 Mn |